Stock Movers Renewables Surge, Bayer Beats Estimates, Munich Re Underperforms
May 13, 2025
Renewable energy stocks are soaring in Europe, thanks to better-than-expected news about U.S. tax incentives. Bayer’s shares are also on the rise, driven by strong demand for its innovative cancer and kidney treatments, despite declining agricultural sales. Meanwhile, Munich Re faces a rough patch, with shares tumbling after a profit slump attributed to losses from wildfires, although its solvency remains strong. The contrasting fortunes of these companies shed light on the current dynamics in the market.
AI Snips
Chapters
Transcript
Episode notes
Renewables Incentives Extended to 2031
- US House Republicans proposed to phase out incentives for clean energy, but companies have until 2031 to benefit from credits.
- This delay is better than feared, causing a surge in renewable energy stocks in Europe.
Bayer Pharma Fuels Stock Rise
- Bayer's earnings beat expectations driven by strong demand for new cancer and kidney medicines.
- This pharma strength offsets challenges Bayer faces in its agricultural and litigation areas.
Munich Re Hit by Wildfire Claims
- Munich Re expects a €1.1 billion hit from California wildfires, causing a profit slump and stock decline.
- Despite the loss, analysts note Munich Re's solvency remains above consensus levels.